IK 01400
Alternative Names: IK-01400Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator InterK Peptide Therapeutics
- Class Analgesics; Anti-inflammatories; Peptides
- Mechanism of Action Protein kinase G inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Neuropathic pain; Pain
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Neuropathic-pain in Australia (Intrathecal, Injection)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Pain in Australia (Intraperitoneal, Injection)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Pain in Australia (IV, Injection)